63 related articles for article (PubMed ID: 15653552)
1. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
Huang JW; Shiau CW; Yang YT; Kulp SK; Chen KF; Brueggemeier RW; Shapiro CL; Chen CS
Mol Pharmacol; 2005 Apr; 67(4):1342-8. PubMed ID: 15653552
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
von Schwarzenberg K; Held SA; Schaub A; Brauer KM; Bringmann A; Brossart P
Cell Mol Life Sci; 2009 Apr; 66(7):1295-308. PubMed ID: 19252820
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
Shiau CW; Yang CC; Kulp SK; Chen KF; Chen CS; Huang JW; Chen CS
Cancer Res; 2005 Feb; 65(4):1561-9. PubMed ID: 15735046
[TBL] [Abstract][Full Text] [Related]
4. The role of peroxisome proliferator-activated receptors in the tumor microenvironment, tumor cell metabolism, and anticancer therapy.
Sun J; Yu L; Qu X; Huang T
Front Pharmacol; 2023; 14():1184794. PubMed ID: 37251321
[TBL] [Abstract][Full Text] [Related]
5. PPAR-γ Modulators as Current and Potential Cancer Treatments.
Chi T; Wang M; Wang X; Yang K; Xie F; Liao Z; Wei P
Front Oncol; 2021; 11():737776. PubMed ID: 34631571
[TBL] [Abstract][Full Text] [Related]
6. Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells.
Tilekar K; Upadhyay N; Schweipert M; Hess JD; Macias LH; Mrowka P; Meyer-Almes FJ; Aguilera RJ; Iancu CV; Choe JY; Ramaa CS
Eur J Pharm Sci; 2020 Nov; 154():105512. PubMed ID: 32801003
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer.
Yoon JK; Byeon HE; Ko SA; Park BN; An YS; Lee HY; Lee YW; Lee SJ
Sci Rep; 2020 Mar; 10(1):4713. PubMed ID: 32170185
[TBL] [Abstract][Full Text] [Related]
8. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.
Cheng HS; Tan WR; Low ZS; Marvalim C; Lee JYH; Tan NS
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614690
[TBL] [Abstract][Full Text] [Related]
9. Ethanol extracts from the branch of Taxillus yadoriki parasitic to Neolitsea sericea induces cyclin D1 proteasomal degradation through cyclin D1 nuclear export.
Park SB; Park GH; Kim HN; Song HM; Son HJ; Park JA; Kim HS; Jeong JB
BMC Complement Altern Med; 2018 Jun; 18(1):189. PubMed ID: 29925351
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/β-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis.
Vallée A; Lecarpentier Y
Front Immunol; 2018; 9():745. PubMed ID: 29706964
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between the Androgen Receptor and PPAR Gamma Signaling Pathways in the Prostate.
Olokpa E; Moss PE; Stewart LV
PPAR Res; 2017; 2017():9456020. PubMed ID: 29181019
[TBL] [Abstract][Full Text] [Related]
12. The pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2.
Watanabe M; Iizumi Y; Sukeno M; Iizuka-Ohashi M; Sowa Y; Sakai T
Oncogenesis; 2017 Apr; 6(4):e311. PubMed ID: 28368390
[TBL] [Abstract][Full Text] [Related]
13. Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions.
Berthe A; Flament S; Grandemange S; Zaffino M; Boisbrun M; Mazerbourg S
Cell Cycle; 2016 Dec; 15(24):3402-3412. PubMed ID: 27753533
[TBL] [Abstract][Full Text] [Related]
14. Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis.
Bandera Merchan B; Tinahones FJ; Macías-González M
PPAR Res; 2016; 2016():2308249. PubMed ID: 27579030
[TBL] [Abstract][Full Text] [Related]
15. The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.
Bartels LE; Mattheolabakis G; Vaeth BM; LaComb JF; Wang R; Zhi J; Komninou D; Rigas B; Mackenzie GG
Carcinogenesis; 2016 Apr; 37(4):420-429. PubMed ID: 26905586
[TBL] [Abstract][Full Text] [Related]
16. Anti-Proliferative Effect of Naringenin through p38-Dependent Downregulation of Cyclin D1 in Human Colorectal Cancer Cells.
Song HM; Park GH; Eo HJ; Lee JW; Kim MK; Lee JR; Lee MH; Koo JS; Jeong JB
Biomol Ther (Seoul); 2015 Jul; 23(4):339-44. PubMed ID: 26157550
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.
Aouali N; Broukou A; Bosseler M; Keunen O; Schlesser V; Janji B; Palissot V; Stordeur P; Berchem G
PLoS One; 2015; 10(6):e0130339. PubMed ID: 26091518
[TBL] [Abstract][Full Text] [Related]
18. Diabetes and its link with cancer: providing the fuel and spark to launch an aggressive growth regime.
Joshi S; Liu M; Turner N
Biomed Res Int; 2015; 2015():390863. PubMed ID: 25961014
[TBL] [Abstract][Full Text] [Related]
19. In vitro anti-proliferative activity of alcoholic stem extract of Coscinium fenestratum in human colorectal cancer cells.
Rojsanga P; Sukhthankar M; Krisanapun C; Gritsanapan W; Lawson DB; Baek SJ
Exp Ther Med; 2010 Jan; 1(1):181-186. PubMed ID: 23136612
[TBL] [Abstract][Full Text] [Related]
20. Effect of troglitazone on radiation sensitivity in cervix cancer cells.
An Z; Liu X; Song H; Choi C; Kim WD; Yu JR; Park WY
Radiat Oncol J; 2012 Jun; 30(2):78-87. PubMed ID: 22984686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
